Crownbio provides a “gold-standard” collection of well-characterized models and services for drug discovery to help its clients reduce the attrition rate of candidate compounds, before they enter the clinic.
Crownbio – cancer Immunotherapy and xenograft models
CrownBio is a Preclinical CRO with expertise in the disease areas of Oncology and Metabolic Disease. CrownBio aims to help the world-wide research community turn cancer from an incurable into a manageable, chronic disease and discover new targets and therapies in the treatment of metabolic diseases. As drug discovery continues to rapidly evolve, there is a growing need to screen candidates earlier and with more patient-relevant models, which more closely reflect the situation in the clinic and therefore help improve the selection of drug candidates. CrownBio’s unique collection of ready-to-run, well-validated in vitro and in vivo models, expertise in model development, comprehensive drug discovery platforms, and global capacity enable them to deliver the results you need, today. Its comprehensive drug discovery services and unique portfolio of models for both Oncology and Metabolic Diseases enable our customers to significantly accelerate and improve the quality of their decision-making process about which candidates to move into the clinic. CrownBio’s proprietary HuPhage antibody phage display system and its robust production and Protein Engineering capability have been deployed to support multiple drug development programs by both large pharmaceutical and small biotech companies.
Founded in 2006, CrownBio is headquartered in the heart of Silicon Valley, with wholly-owned research facilities in Kannapolis (USA), San Diego (USA), Beijing (China), Taicang near Shanghai (China), Taiwan and Loughborough (UK). Its team of experts includes highly trained PhD and MS scientists from around the world. The leadership team has a deep understanding of the pharmaceutical industry and is composed by Guo Liang Yu, Alex Wu, Bing Zhu, Laurie Heilmann, Yining Qi, Yixin Wang and Henry Li.
More about Crownbio: www.crownbio.com